

flame resistance, and membrane separation characteristics; and

(2) develop mechanisms to transfer such manufacturing technologies to United States industries.

(c) Reports

The Council, through the Director of the National Nanotechnology Coordination Office, shall submit to the Senate Committee on Commerce, Science, and Transportation and the House of Representatives Committee on Science—

(1) within 6 months after December 3, 2003, a report identifying which agency shall be the lead agency and which other agencies, if any, will be responsible for establishing the Centers described in this section; and

(2) within 18 months after December 3, 2003, a report describing how the Centers described in this section have been established.

(Pub. L. 108-153, § 9, Dec. 3, 2003, 117 Stat. 1930.)

CHANGE OF NAME

Committee on Science of House of Representatives changed to Committee on Science and Technology of House of Representatives by House Resolution No. 6, One Hundred Tenth Congress, Jan. 5, 2007. Committee on Science and Technology of House of Representatives changed to Committee on Science, Space, and Technology of House of Representatives by House Resolution No. 5, One Hundred Twelfth Congress, Jan. 5, 2011.

§ 7509. Definitions

In this chapter:

(1) Advisory Panel

The term “Advisory Panel” means the President’s National Nanotechnology Advisory Panel established or designated under section 7503 of this title.

(2) Nanotechnology

The term “nanotechnology” means the science and technology that will enable one to understand, measure, manipulate, and manufacture at the atomic, molecular, and supramolecular levels, aimed at creating materials, devices, and systems with fundamentally new molecular organization, properties, and functions.

(3) Program

The term “Program” means the National Nanotechnology Program established under section 7501 of this title.

(4) Council

The term “Council” means the National Science and Technology Council or an appropriate subgroup designated by the Council under section 7501(c) of this title.

(5) Advanced technology user facility

The term “advanced technology user facility” means a nanotechnology research and development facility supported, in whole or in part, by Federal funds that is open to all United States researchers on a competitive, merit-reviewed basis.

(6) Program component area

The term “program component area” means a major subject area established under section

7501(c)(2) of this title under which is¹ grouped related individual projects and activities carried out under the Program.

(Pub. L. 108-153, § 10, Dec. 3, 2003, 117 Stat. 1931.)

CHAPTER 102—FAIRNESS TO CONTACT LENS CONSUMERS

| | |
|-------|---|
| Sec. | |
| 7601. | Availability of contact lens prescriptions to patients. |
| 7602. | Immediate payment of fees in limited circumstances. |
| 7603. | Prescriber verification. |
| 7604. | Expiration of contact lens prescriptions. |
| 7605. | Content of advertisements and other representations. |
| 7606. | Prohibition of certain waivers. |
| 7607. | Rulemaking by Federal Trade Commission. |
| 7608. | Violations. |
| 7609. | Study and report. |
| 7610. | Definitions. |

§ 7601. Availability of contact lens prescriptions to patients

(a) In general

When a prescriber completes a contact lens fitting, the prescriber—

(1) whether or not requested by the patient, shall provide to the patient a copy of the contact lens prescription; and

(2) shall, as directed by any person designated to act on behalf of the patient, provide or verify the contact lens prescription by electronic or other means.

(b) Limitations

A prescriber may not—

(1) require purchase of contact lenses from the prescriber or from another person as a condition of providing a copy of a prescription under subsection (a)(1) or (a)(2) or verification of a prescription under subsection (a)(2);

(2) require payment in addition to, or as part of, the fee for an eye examination, fitting, and evaluation as a condition of providing a copy of a prescription under subsection (a)(1) or (a)(2) or verification of a prescription under subsection (a)(2); or

(3) require the patient to sign a waiver or release as a condition of verifying or releasing a prescription.

(Pub. L. 108-164, § 2, Dec. 6, 2003, 117 Stat. 2024.)

EFFECTIVE DATE

Pub. L. 108-164, § 12, Dec. 6, 2003, 117 Stat. 2028, provided that: “This Act [enacting this chapter and provisions set out as a note below] shall take effect 60 days after the date of the enactment of this Act [Dec. 6, 2003].”

SHORT TITLE

Pub. L. 108-164, § 1, Dec. 6, 2003, 117 Stat. 2024, provided that: “This Act [enacting this chapter and provisions set out as a note above] may be cited as the ‘Fairness to Contact Lens Consumers Act’.”

§ 7602. Immediate payment of fees in limited circumstances

A prescriber may require payment of fees for an eye examination, fitting, and evaluation be-

¹ So in original. Probably should be “are”.